Immucor builds blood transfusion portfolio
This article was originally published in The Gray Sheet
Immucor gains BioArray Solutions' BeadChip DNA analysis system for antigen determination for donors and recipients of blood transfusions under a $117 million acquisition deal announced March 11. The cash deal also gives Immucor a 19% equity interest in a new spin-off entity that will commercialize BioArray technology outside the fields of blood transfusion and transplantation. Immucor makes automated instruments and reagents that detect and identify the properties of cell and serum components of blood prior to transfusions
You may also be interested in...
Blood transfusion testing product maker Immucor will gain added financial resources for future growth following investment firm TPG Capital’s purchase of the company for $1.97 billion, the firm announced July 5.
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.